| Symbol | AEON |
|---|---|
| Name | AEON BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4040 MACARTHUR BLVD,SUITE 260, NEWPORT BEACH, California, 92660, United States |
| Telephone | (949) 354-6499 |
| Fax | — |
| — | |
| Website | https://www.aeonbiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Additional info from NASDAQ: |
Bencich John 🟢 acquired 754.7K shares of AEON Biopharma, Inc. (AEON) Transaction Date: Apr 02, 2026 | Filing ID: 039697
Read moreAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Read more(99% Neutral) AEON BIOPHARMA, INC. (AEON) Reports Q1 2026 Financial Results
Read moreAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
Read moreNew Form 3 - AEON Biopharma, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001104659-26-039696 <b>Size:</b> 9 KB
Read more(30% Negative) AEON BIOPHARMA, INC. (AEON) Reports Q1 2026 Financial Results
Read moreAEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
Read moreAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
Read moreAEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05016661 | Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatmen… | Phase2 | Migraine | Terminated | 2021-10-19 | 2024-08-30 | ClinicalTrials.gov |
| NCT04871451 | Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatmen… | Phase2 | Cervical Dystonia | Completed | 2021-07-27 | 2023-07-24 | ClinicalTrials.gov |
| NCT04849988 | A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment… | Phase2 | Cervical Dystonia | Completed | 2021-03-29 | 2022-07-11 | ClinicalTrials.gov |
| NCT04845178 | Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adul… | Phase2 | Migraine | Completed | 2021-03-01 | 2024-08-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | DRUG | Phase PHASE2 | Cervical Dystonia | COMPLETED | NCT04849988 |
| ABP-450 | DRUG | Phase PHASE2 | Migraine | TERMINATED | NCT05016661 |